SEC EDGARSEP 31 min read$BMRN

Davis George Eric sold $1.2M of BMRN

Davis George Eric (EVP, Chief Legal Officer) sold 17,557 shares of BIOMARIN PHARMACEUTICAL INC (BMRN) at $66.28 ($1.16M total) on 2026-09-02.

Original reporting

SEC EDGAR · Davis George Eric

Published Sep 3, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 4, 2026, 7:14 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$BMRN

Bearish

medium confidence

Mentioned

$BMRN

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$BMRNBearishLow

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short-term positioning.

Market read

Insider sale adds modest negative pressure on BMRN; limited broader market effect.

What to watch

No 10b5-1 plan and the officer's role may suggest a strategic move unrelated to fundamentals.

Relevance 6/10Novelty 7/10Timing: Filed after market close on 2026-09-02

Background

Form 4 filings disclose insider transactions; traders monitor them for sentiment cues.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BMRNBearishMedium confidence

Context

EVP and Chief Legal Officer Davis George Eric sold 17,557 shares for $1.16M, reducing his stake to 61,003 shares.

Expected impact

Possible modest downside of 1-2% over the next few days.

Evidence & confidence

The sale size is moderate for a senior officer; no 10b5-1 plan indicates discretionary action.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and not sector-wide.

Regional

U.S. market only; no regional ripple.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be for personal liquidity and not reflect company outlook.

Key entities

Company
Biomarin Pharmaceutical Inc
US-listed biotech firm (ticker BMRN).
Individual
Davis George Eric
EVP and Chief Legal Officer of Biomarin.

Read at source ← All news

SEP 17

$BMRNMedAI 8/10

What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders

BioMarin Pharmaceutical reported positive Phase 3 trial data for VOXZOGO in treating hypochondroplasia, supporting an FDA application. The data may expand VOXZOGO's market and impact BioMarin's growth strategy. Analysts project revenue of $5.0B and earnings of $1.3B by 2029, with a potential 41% upside. Risks include pricing pressure, competition, and high R&D costs.

simplywall.st3 min

SEP 14

$BMRNLow

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

BioMarin Pharmaceutical Inc. (BMRN) appointed Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to its Board of Directors. Plenge brings extensive experience in drug discovery and pharmaceutical industry leadership. BioMarin focuses on developing medicines for rare genetic conditions.

prnewswire.com2 min

SEP 12

$BMRNMed

BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

BioMarin (BMRN) shares rose 5% after settling a global patent dispute with Ascendis (ASND) over Yuviwel, an achondroplasia drug. Ascendis will pay BioMarin royalties of 20% of US net sales and 18% internationally until 2030. The settlement resolves pending litigation, including a US ITC investigation. Both companies framed the outcome positively, highlighting long-term benefits and commercial flexibility.

insidermonkey.com2 min

SEP 11

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

rttnews.com3 min

SEP 9

$BMRNMedAI 9/10

BioMarin's VOXZOGO Hits Phase 3 Growth Endpoint In Hypochondroplasia

BioMarin Pharmaceutical (BMRN) reported that its Phase 3 study of VOXZOGO in children with hypochondroplasia met its primary endpoint, showing significant growth improvements. The company plans to submit a supplemental FDA application and expects a potential 2027 launch. BMRN stock is currently at $64.80, up 0.26%.

rttnews.com2 min